Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
Background The addition of monoclonal antibody therapy against GD2 to the treatment of high-risk neuroblastoma led to improved responses in patients. Nevertheless, administration of GD2 antibodies against neuroblastoma is associated with therapy-limiting neuropathic pain. This severe pain is evoked...
Saved in:
| Main Authors: | Stefan Nierkens, Niels Eijkelkamp, Maaike Nederend, Jeanette Leusen, Mitchell Evers, Marjolein Stip, Kaylee Keller, Hanneke Willemen, Marco Jansen, Chilam Chan, Kevin Budding, Thomas Valerius, Friederike Meyer-Wentrup |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/10/e003163.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
GD2 targeting CAR T cells for neuroblastoma
by: John Anderson, et al.
Published: (2024-12-01) -
The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma
by: Léon Raymakers, et al.
Published: (2025-04-01) -
Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy
by: Jincan Zan, et al.
Published: (2024-04-01) -
Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro.
by: Kuntida Kitidee, et al.
Published: (2025-01-01) -
Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro
by: Kuntida Kitidee, et al.
Published: (2025-01-01)